A Phase II, Multicenter, Open-Label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR mutated NSCLC and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive NSCLC
A Phase II, Multicenter, Open-Label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR mutated NSCLC and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive NSCLC